High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.

Emidio Scarpellini, Maurizio Gabrielli, Ernesto Cristiano Lauritano, Andrea Lupascu, Giuseppe Merra, Giovanni Cammarota, Immacolata Alessia Cazzato, Giovanni Battista Gasbarrini, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

99 Citazioni (Scopus)


BACKGROUND: Rifaximin is a broad spectrum non-absorbable antibiotic used for treatment of small intestinal bacterial overgrowth. Doses of 1200 mg/day showed a decontamination rate of 60% with low side-effects incidence. AIMS: To assess efficacy, safety and tolerability of rifaximin 1600 mg with respect to 1200 mg/day for small intestinal bacterial overgrowth treatment. METHODS: Eighty consecutive small intestinal bacterial overgrowth patients were enrolled. Diagnosis of small intestinal bacterial overgrowth based the clinical history and positivity to H(2)/CH(4) glucose breath test. Patients were randomized in two 7-day treatment groups: rifaximin 1600 mg (group 1); rifaximin 1200 mg (group 2). Glucose breath test was reassessed 1 month after. Compliance and side-effect incidence were also evaluated. RESULTS: One drop-out was observed in group 1 and two in group 2. Glucose breath test normalization rate was significantly higher in group 1 with respect to group 2 both in intention-to-treat (80% vs. 58%; P < 0.05) and per protocol analysis (82% vs. 61%; P < 0.05). No significant differences in patient compliance and incidence of side effects were found between groups. CONCLUSIONS: Rifaximin 1600 mg/day showed a significantly higher efficacy for small intestinal bacterial overgrowth treatment with respect to 1200 mg with similar compliance and side-effect profile.
Lingua originaleEnglish
pagine (da-a)781-786
Numero di pagine6
Stato di pubblicazionePubblicato - 2007


  • Rifaximin
  • SIBO


Entra nei temi di ricerca di 'High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.'. Insieme formano una fingerprint unica.

Cita questo